Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM7Z6Y
|
|||
| Drug Name |
Lampalizumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Geographic retinal atrophy [ICD-11: 9B78.9] | Phase 3 | [1] | |
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor D (CFD) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Platelet degranulation | |||
| Alternative complement activation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Adipogenesis | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02745119) Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT). U.S. National Institutes of Health. | |||
| REF 2 | In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.